Following the negative short-term impact of the COVID-19 pandemic, the Asia Pacific biosurgical agent market will grow at a modest rate, driven by growing surgical procedure volumes due to expanding aging population and the rising prevalence of diseases associated with aging, obesity, diabetes, and cardiovascular disease, in addition to rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, growing concerns over product cost and competition from local competitors will limit ASP growth in this market, thus hindering revenue expansion to some extent.
This Medtech 360 Report provides high-level market metrics for biosurgical agents in the Asia Pacific region, including country-level data for major countries and aggregate data for the rest of the Asia Pacific region, across a 10-year period.
- Biosurgical Agents - Market Insights - Asia Pacific (Supplemental)
Author(s): Hebri Nandita Mallya; Sumit Jain, MS Pharm
Hebri Nandita Mallya is a research associate within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, specializing in Diagnostic Imaging Systems market. Hebri Nandita Mallya holds a Bachelor's degree in Biotechnology, Chemistry and Zoology from Christ University, Bangalore, and a Master's degree in Medical Biochemistry from Manipal Academy of Higher Education.
Sumit Jain is a senior analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor's degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master's degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.